|
English
|
正體中文
|
简体中文
|
2826152
|
|
???header.visitor??? :
31796420
???header.onlineuser??? :
1216
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"kim ds"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2018-07-16 |
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease
|
Chen, S;Yu, SJ;Li, Y;Lecca, D;Glotfelty, E;Kim, HK;Choi, HI;Hoffer, BJ;Greig, NH;Kim, DS;Wang, Y |
| 國家衛生研究院 |
2018-07-16 |
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease [Erratum: Scientific Reports. 2018 Jul 16;8:Article number 10722.]
|
Chen, S;Yu, SJ;Li, Y;Lecca, D;Glotfelty, E;Kim, HK;Choi, HI;Hoffer, BJ;Greig, NH;Kim, DS;Wang, Y |
| 國家衛生研究院 |
2017-09 |
A new treatment strategy for Parkinson's disease through the gut-brain axis: The glucagon-like peptide-1 receptor pathway
|
Kim, DS;Choi, HI;Wang, Y;Luo, Y;Hoffer, BJ;Greig, NH |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
